ForePass is aimed at replicating Roux-en-Y Gastric Bypass (RYGB) throughout

A fully cut-less procedure

It is the first endoscopic procedure that replicates the mechanism of action of RYGB without cuts or sutures

The Device

Keyron’s ForePass is the first device truly designed to reverse insulin resistance

A next-generation technology platform

ForePass replicates various types of metabolic surgery procedures without making a single cut

The final ForePass device may differ in size and characteristics to that shown in this video.

A study of 30 rodents

Superior Efficacy in Rodents

Conclusion: ForePass reduces body weight, glycemia and insulin resistance, and liver fat deposition to the same level of gastric bypass surgery

We demonstrated a full reversal of diabetes and NASH, and weight loss, to levels not statistically different from gastric bypass surgery

Note: ForePass was previously named Sleeveballoon.

In Progress

Safety & Efficacy
in Swines

We are currently undergoing swine studies in the United States and Italy. Results from an independent study led and funded by Mayo Clinic suggests that a combination of a balloon and duodenal sleeve is:

Successful Deployment & Retrieval In Swines

Swine Studies In Progress

Treatment options for Diabesity

Bypass Surgery

Only effective treatment for diabetes and obesity, leads to full diabetes remission and major weight loss

However, it also leads to 10-15% complications and death in ∼1% of cases’

Gastric Balloons

Widely considered safe, but ineffective on diabetes.

The fact that balloons move throughout the stomach fails to maximize weight loss

Duodenal Liners

Mildly effective on diabetes and weight loss, none of the current lining technologies have shown a reversal of diabetes

All current liners involve some damage to internal organs and have not been approved by FDA

ForePass

As effective on diabetes and obesity as gastric bypass surgery in rodent models

Designed to replicate gastric bypass surgery without any cuts to internal organs

Next steps

We are due to complete preclinical work by 2022.
First in human study is expected to start in 2023.

X

Roux-en-Y Gastric Bypass (RYGB)

  • Roux-en-Y Gastric Bypass (RYGB) is an effective operation that determines type 2 diabetes remission and reversion of insulin resistance.
  • A large portion of the stomach, the entire duodenum and the initial part of the jejunum are bypassed from food transit after RYGB. The bypass of the duodenum and the jejunum covers a central role in the improvement of glycemic control.